Research confirms benefits of side-actuated nasal spray
Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.
The side-actuated nasal spray consists of a standard actuator coupled with a customisable shell and cap.
The research, carried out in the UK last November involving 10 regular nasal spray users, as well as six doctors (GPs and ENT specialists), showed that the side-actuated delivery device has the three advantages mentioned above.
Patients also thought a slightly longer nozzle would improve the placement of the device in the nostril when the device is actuated, and Valois will further investigate this.
The company says new user research will be carried out in the US in the coming months to confirm the results of the current study.
You may also like
Research & Development
New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research
Read moreOsaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Trending Articles
You may also like
Research & Development
New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research
Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development
Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery
The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Research & Development
PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific
The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape